Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) is 12.54% higher on its value in year-to-date trading and has touched a low of $377.85 and a high of $519.88 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRTX stock was last observed hovering at around $455.22 in the last trading session, with the day’s loss setting it -2.02%.
Currently trading at $453.20, the stock is 0.77% and 3.02% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.14 million and changing -0.44% at the moment leaves the stock -1.90% off its SMA200. VRTX registered 7.16% gain for a year compared to 6-month loss of -2.43%. The firm has a 50-day simple moving average (SMA 50) of $440.1228 and a 200-day simple moving average (SMA200) of $461.6784.
The stock witnessed a 9.64% gain in the last 1 month and extending the period to 3 months gives it a -12.30%, and is -7.21% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.37% over the week and 2.55% over the month.
Vertex Pharmaceuticals, Inc (VRTX) has around 5400 employees, a market worth around $116.71B and $11.01B in sales. Fwd P/E is 22.40. Profit margin for the company is -4.87%. Distance from 52-week low is 19.94% and -12.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-2.96%).
with sales reaching $2.85B over the same period.The EPS is expected to grow by 4143.63% this year, but quarterly earnings will post 8.53% year-over-year. Quarterly sales are estimated to grow 5.88% in year-over-year returns.
The shares outstanding are 256.90M, and float is at 256.19M with Short Float at 1.78%.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 26.71 million shares valued at $12.52 billion. The investor’s holdings represent 10.3439 of the VRTX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 22.98 million shares valued at $10.77 billion to account for 8.8983 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 21.31 million shares representing 8.2542 and valued at over $9.99 billion, while STATE STREET CORP holds 4.5415 of the shares totaling 11.73 million with a market value of $5.5 billion.
Vertex Pharmaceuticals, Inc (VRTX) Insider Activity
The most recent transaction is an insider sale by Tatsis Ourania, the company’s EVP, Chief Reg. & Quality Off. SEC filings show that Tatsis Ourania sold 310 shares of the company’s common stock on Feb 11 ’25 at a price of $459.83 per share for a total of $0.14 million. Following the sale, the insider now owns 64021.0 shares.
Vertex Pharmaceuticals, Inc disclosed in a document filed with the SEC on Feb 11 ’25 that Biller Jonathan (EVP and Chief Legal Officer) sold a total of 3,433 shares of the company’s common stock. The trade occurred on Feb 11 ’25 and was made at $459.87 per share for $1.58 million. Following the transaction, the insider now directly holds 16330.0 shares of the VRTX stock.
Still, SEC filings show that on Feb 11 ’25, Atkinson Edward Morrow III (EVP, Chief Technical Ops. Off.) disposed off 1,747 shares at an average price of $459.83 for $0.8 million. The insider now directly holds 23,225 shares of Vertex Pharmaceuticals, Inc (VRTX).
